Loading...

Table of Content

    25 October 2025, Volume 24 Issue 05 Previous Issue   
    For Selected: Toggle Thumbnails
    Expert forum
    Renal denervation for treatment of hypertension: current status and challenges
    JIANG Kaiwen, DONG Hui, JIANG Xiongjing
    2025, 24 (05):  465-470.  DOI: 10.16150/j.1671-2870.2025.05.001
    Abstract ( 11 )   HTML ( 2 )   PDF (503KB) ( 4 )  

    Renal denervation (RDN) represents a novel therapeutic approach for hypertension and has made significant progress over the past decade. This study reviews the main evidence from domestic and international randomized controlled clinical trials of RDN for hypertension treatment and provides an in-depth exploration of the critical unresolved issues in RDN therapy. These include how to establish precise patient selection systems, optimize renal nerve ablation techniques and intraoperative evaluation standards for denervation efficacy, and conduct large-scale, long-term follow-up stu-dies to evaluate benefits on cardiovascular hard endpoints.

    Figures and Tables | References | Related Articles | Metrics
    Prevalence, diagnosis, and treatment progress of resistant hypertension
    MA Zhiqiang, LIN Zixin, WU Hao, WANG Zaijia, ZHANG Xiangtao, DONG Yifei
    2025, 24 (05):  471-484.  DOI: 10.16150/j.1671-2870.2025.05.002
    Abstract ( 10 )   HTML ( 2 )   PDF (1019KB) ( 4 )  

    Resistant hypertension (RH), defined as uncontrolled blood pressure despite the use of optimal combination therapy, represents a major clinical treatment challenge. Its underlying mechanism is a complex pathophysiological network involving multiple interacting systems, primarily including excessive activation of the renin-angiotensin-aldosterone system (RAAS), increased excitability of the sympathetic nervous system (SNS), genetic predisposition, vascular endothelial dysfunction, and inflammatory responses. These are closely associated with significantly increased cardiovascular risk. RH accounts for 1.9%-18.0% of the hypertensive population, with most studies indicating about 10% of hypertensive patients have RH. Evaluation of RH requires standardized blood pressure measurement (with a combination of office and home blood pressure recommended), and objective evaluation of patient medication adherence (with poor adherence observed in nearly 50% of patients). Screening for secondary causes of hypertension is crucial. For example, the prevalence of primary aldosteronism among RH patients reaches 17%-23% (with a screening rate of only 2.1%). Over 50% of patients with sleep apnea syndrome have hypertension, and renal artery stenosis hypertension accounts for about 24% of RH patients. Comprehensive identification of the underlying causes of hypertension can significantly improve blood pressure control and prognosis. RH treatment emphasizes lifestyle interventions [such as DASH (dietary approaches to stop hypertension) diet, which can reduce blood pressure by about 6.97 mmHg], as well as drug and device-based therapies. Spironolactone, as the preferred fourth-line agent, can reduce systolic blood pressure by about 8.70 mmHg. Among novel agents, the aldosterone synthase inhibitors lorundrostat and baxdrostat reduced systolic blood pressure by approximately 9.1 mmHg and 9.8 mmHg compared with placebo, respectively, while aprocitentan lowered systolic blood pressure by about 3.7 mmHg compared with placebo. Renal sympathetic denervation (RDN) can persistently reduce ambulatory systolic blood pressure by about 13.6 mmHg, with good safety. Looking ahead, driven by both evidence-based medicine and innovative therapies (new drugs and devices), RH treatment is undergoing a paradigm shift centered on precision and individualized care, which is expected to bring revolutionary impact on the improvement of patient prognosis.

    Figures and Tables | References | Related Articles | Metrics
    Academic trend at home and abroad
    Interpretation of global stroke report data in 2025: gradient evolution and precise management of stroke burden
    TANG Chunhua, GUO Lu, ZHANG Lili
    2025, 24 (05):  485-497.  DOI: 10.16150/j.1671-2870.2025.05.003
    Abstract ( 105 )   HTML ( 5 )   PDF (777KB) ( 30 )  

    In 2021, there were 93.816 million prevalent cases of stroke worldwide [age-standardized prevalence rate(ASPR) 1 099/100 000], with 11.946 million new cases in that year [age-standardized incidence rate(ASIR) 142/100 000]. Among these new cases, ischemic stroke (IS), intracerebral hemorrhage (ICH), and subarachnoid hemorrhage (SAH) accounted for 65.3% (7.804 million), 28.8% (3.444 million), and 5.8% (0.697 million), respectively. In the same year, stroke caused 7.253 million deaths, accounting for 10.7% of all global deaths. Deaths caused by IS, ICH, and SAH accounted for 49.5% (3.591 million), 45.6% (3.308 million), and 4.9% (353 000), respectively. In 2021, stroke remained the second leading cause of death worldwide, with its core disease burden indicator — disability-adjusted life years (DALYs) — exceeding 160 million, ranking third among all global total disease burdens. In terms of economic burden, the global direct medical costs and productivity losses caused by stroke reached 890 billion USD in 2021 (accounting for 0.66% of the global GDP), and are projected to exceed 1.8 trillion USD by 2050 if the current growth rate persists. The global stroke burden exhibits a dual trend of "increasing absolute numbers but decreasing age-standardized rates". Low- and middle-income countries bear most of the disease burden, and the incidence of stroke shows a coexistence of younger and older onset. In terms of risk factors, the burden of traditional behavior-related risks has decreased, while the attributable burden of metabolic and climate-related risks is rapidly increasing. China bears the heaviest stroke burden globally, characterized by a “four-high” pattern of “high incidence, high prevalence, medium-to-high mortality, and medium-to-high DALYs”, with significant urban-rural and regional disparities. This condition results from the combined effects of accelerated population aging and continuously increasing exposure to risk factors. In 2021, there were 26.335 million prevalent cases in China, with ASPR of 1 301.4/100 000. In 2021, there were 4.09 million new stroke cases in China (ASIR 204.8/100 000), accounting for 34.2% of all new global cases—far exceeding China's proportion of the world's population (about 20%). IS accounted for 67.8% [2.772 million cases, age-standardized incidence rate (ASIR) 135.8/100 000], and ICH accounted for 28.7% (1.173 million cases, ASIR 61.2/100 000). The annual total economic burden of stroke in China has exceeded 400 billion RMB, with its proportion in the national healthcare expenditure continuing to increase. Direct medical costs account for about 60%, while indirect costs (including productivity losses and caregiving expenses) account for 40%, imposing a dual pressure on both society and families. To address this challenge, a stratified precision prevention and control system centered on the coordination of "policy-healthcare-society" should be established, covering primordial, primary, and secondary prevention levels. Emphasis should be placed on cross-sector collaboration, data-driven approaches, and international experience sharing to achieve effective control of the stroke burden and promote global health equity.

    Figures and Tables | References | Related Articles | Metrics
    Original articles
    Comparative study on diagnostic performance of Acquire fine-needle biopsy and fine-needle aspiration in endoscopic ultrasonography-guided tissue acquisition for type 1 autoimmune pancreatitis
    SHEN Xiaonan, ZHOU Chunhua, ZHANG Benyan, GAO Lili, ZHANG Ling, HE Xiangyi, LIU Chenxiao, ZHANG Xianda, ZHANG Yao, WU Wei, GONG Tingting, ZHANG Tianyu, LIU Lei, ZOU Duowu, ZHANG Minmin
    2025, 24 (05):  498-504.  DOI: 10.16150/j.1671-2870.2025.05.004
    Abstract ( 9 )   HTML ( 0 )   PDF (553KB) ( 2 )  

    Objective: To compare the application value of 22G-Acquire fine-needle biopsy (FNB) and conventional 22G fine-needle aspiration (FNA) in the cytological diagnosis of type 1 autoimmune pancreatitis (AIP). Methods: This retrospective study included 57 patients who were highly suspected of type 1 AIP based on imaging and serology and were admitted to our hospital from January 2020 to January 2024. According to the type of needle used, patients were divided into two groups: the FNB group (22G-Acquire needle, n=30) and the FNA group (n=27) to evaluate the histological diagnostic levels of type 1 AIP obtained by two needle types under endoscopic ultrasonography (EUS)-guided sampling. Results: In the FNA group, lymphoplasmacytic infiltration was observed in 33.3% of puncture tissues, while storiform fibrosis was identified in only 22.2%. Level 2 histological evidence was achieved in 11.1% of cases, with no Level 1 evidence. In the FNB group, lymphoplasmacytic infiltration was observed in 63.3% of puncture tissues, and storiform fibrosis was present in 83.3% of puncture tissues. Level 1 evidence was observed in 3.3% of cases, Level 2 in 56.7%, and combined Level 1+2 in 60%. Obliterative phlebitis was not detected in either group. Two cases met the criteria of IgG4-positive plasma cells >10 per high power field (HPF), with 1 case each in FNB group and FNA group. Compared to the FNA group, the FNB group showed significant advantages in the detection of lymphoplasmacytic infiltration (63.3% vs 33.3%) (P=0.024) and storiform fibrosis (83.3% vs 22.2%) (P<0.001) in the obtained tissues, along with higher evidence levels (P<0.001). Conclusion: The 22G-Acquire needle can obtain higher tissue evidence levels and can be routinely employed for the histological diagnosis of type 1 AIP.

    Figures and Tables | References | Related Articles | Metrics
    Predictive value of serum IGF-1 combined with TPOAb for the occurrence of hypothyroidism after 131I treatment in patients with hyperthyroidism
    ZENG Beibei, HUANG Yi, ZHANG Buteng, HUANG Ronghe, QIN Lihua, ZHOU Qiting
    2025, 24 (05):  505-511.  DOI: 10.16150/j.1671-2870.2025.05.005
    Abstract ( 8 )   HTML ( 1 )   PDF (602KB) ( 4 )  

    Objective To explore the predictive value of serum insulin-like growth factor-1 (IGF-1), thyroid peroxidase antibodies (TPOAb), thyrotropin receptor antibodies (TRAb), and interleukin 17 (IL-17) for the occurrence of hypothyroidism after 131I treatment in patients with hyperthyroidism. Methods A total of 121 patients with hyperthyroidism who received 131I treatment in the Department of Nuclear Medicine of the Second Nanning People's Hospital from January 2022 to June 2023 were enrolled and followed up for one year. Based on the occurrence of hypothyroidism after 131I treatment, patients were divided into the hypothyroidism and non-hypothyroidism groups. The differences in general data and laboratory indicators before treatment between the two groups were compared. Binary logistic regression analysis was performed on the indicators with statistical differences between groups, and the receiver operating characteristic (ROC) curves were constructed to evaluate the predictive value of these indicators for the progression to hypothyroidism in patients with hyperthyroidism after 131I treatment. Results After 131I treatment, there were 55 cases in the hypothyroidism group and 66 cases in the non-hypothyroidism group. The median TPOAb level in the hypothyroidism group was 965.23 IU/mL, significantly higher than that in the non-hypothyroidism group at 188.70 IU/mL. Meanwhile, the median IGF-1 level in the hypothyroi-dism group was 140.97 ng/mL, lower than that in the non-hypothyroidism group at 224.28 ng/mL, with both differences being statistically significant (P<0.001). The regression analysis results showed that elevated IGF-1 level acted as a protective factor against hypothyroidism in patients with hyperthyroidism after 131I treatment, while increased TPOAb level was a risk factor. ROC curve analysis showed that an IGF-1 level <149.00 ng/mL predicted early hypothyroidism with an area under the curve (AUC) of 0.827, and a TPOAb level >473.6 IU/mL yielded an AUC of 0.835. Moreover, the combination of serum IGF-1 and TPOAb yielded the largest AUC of 0.899 for predicting hypothyroidism in patients with hyperthyroidism after 131I treatment, demonstrating the strongest predictive ability. Conclusion Observing the levels of serum IGF-1 combined with TPOAb in patients with hyperthyroidism before 131I treatment demonstrates certain clinical predictive value for the occurrence of hypothyroidism after 131I treatment.

    Figures and Tables | References | Related Articles | Metrics
    Correlation between diffuse hepatic ¹³¹I uptake and functional status of ¹³¹I uptake in lung metastases during post-operative ablation therapy for papillary thyroid carcinom
    WANG Yang, WANG Chao, FU Fan, ZHANG Min, LI Biao, WANG Jin
    2025, 24 (05):  512-517.  DOI: 10.16150/j.1671-2870.2025.05.006
    Abstract ( 8 )   HTML ( 1 )   PDF (942KB) ( 5 )  

    Objective To investigate the auxiliary value of diffuse hepatic ¹³¹I uptake (DHU) levels on post-therapy whole-body scan (Rx-WBS) images in assessing metastatic tumor burden in patients with papillary thyroid cancer (PTC) accompanied by lung metastases who underwent total thyroidectomy followed by radioiodine remnant ablation (RRA) and subsequently received ¹³¹I therapy for non-resectable distant or regional metastases. Methods A total of 22 PTC patients with lung metastases scheduled for ¹³¹I metastatic ablation therapy were retrospectively enrolled from the Department of Nuclear Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, between June 2020 and February 2025. The patients met the following three criteria: (1) total thyroidectomy; (2) completion of ¹³¹I RRA; (3) multiple pulmonary nodules detected on 131I RRA-period whole-body scan or chest CT, with stimulated thyroglobulin (sTg) >10 ng/mL. Bivariate correlation and multiple linear regression models were used to analyze the correlations of target-to-background ratios (TBR) of liver (TBRliver) and lung metastases (TBRlung) for ¹³¹I uptake with clinical parameters including sTg, thyroglobulin antibody (TgAb), and administered ¹³¹I dose. Results TBRliver showed a significant positive correlation with TBRlung (r=0.510, P<0.05). No significant correlations were found between TBRliver and sTg (r=0.218, P=0.331) or administered dose (r=0.334, P=0.128). Multiple linear regression analysis identified TBRlung as an independent influencing factor of TBRliver (β=0.511, 95% CI: 0.053-0.453, P<0.05). Conclusion In PTC patients with lung metastases after thyroidectomy and RRA, TBRliver demonstrates a significant correlation with the functional status of ¹³¹I uptake in lung metastases. Particularly when ¹³¹I scanning shows negative pulmonary nodules, elevated TBRliver may serve as an indicator of the presence of lung metastases.

    Figures and Tables | References | Related Articles | Metrics
    Synergistic expression of survivin and TK1 in breast cancer tissues and its clinical significance
    XU Tu, SHI Chuntao, HAN Wei, YAO Liqian, CHEN Chaobo, FANG Ling, GU Tingting
    2025, 24 (05):  518-528.  DOI: 10.16150/j.1671-2870.2025.05.007
    Abstract ( 8 )   HTML ( 0 )   PDF (2085KB) ( 4 )  

    Objective This study aims to analyze the expression of survivin/BIRC5 and its related genes in breast cancer, as well as their clinicopathological and prognostic roles. Methods The Gene Expression Profiling Interactive Analysis (GEPIA) database was used to analyze survivin expression differences between breast cancer and normal breast tissues, identify the gene most strongly correlated with survivin, and evaluate their association with breast cancer stages. The Kaplan-Meier plotter database was used to assess the relationship between the expression of survivin and related genes and prognosis of breast cancer patients. Immunohistochemistry (IHC) was performed on 96 postoperative breast cancer tissue specimens, collected from January 2016 to March 2019, to validate the expression of survivin and related genes, analyze their correlation, and assess clinicopathological and prognostic significance (5-year overall survival [OS] rate and 5-year disease-free survival [DFS] rate). Results Bioinformatics analysis of the GEPIA database showed that survivin expression was significantly elevated in breast cancer tissues. The gene with the strongest correlation with its expression was thymidine kinase 1 (TK1), which was also over-expressed in breast cancer tissues. Both of them exhibited synergistic expression, increasing with advanced cancer stages (P<0.05) and correlating negatively with recurrence-free survival in breast cancer patients (P<0.001). IHC results from postoperative tissue samples confirmed a significant positive correlation between survivin and TK1 expression levels. Survivin expression correlated with lymph node metastasis and TNM stage (P<0.01), while TK1 correlated with histological grade, lymph node metastasis, and TNM stage (P<0.05). Survivin and TK1 co-expression was observed in 28 cases (29.17%), showing significant associations with higher histological grade, lymph node metastasis, and advanced-stage disease (P<0.05). In prognostic analysis, the five-year OS rate and five-year DFS rate were 61.5% and 47.9%, respectively. Positive survivin (OS HR=2.225, 95%CI: 1.160-4.271, P=0.016; DFS HR=3.594, 95%CI: 2.018-6.401, P<0.001) and TK1 (OS HR=3.176, 95%CI:1.658-6.083, P<0.001; DFS HR=3.609, 95%CI: 2.057-6.330, P<0.001) predicted poorer prognosis, with co-expression showing higher hazard ratios (5-year OS HR=4.486, 95%CI: 2.335-8.617, P<0.001; 5-year DFS HR=4.469, 95%CI: 2.515-7.942, P<0.001). Conclusions Survivin and TK1 exhibit strong synergistic expression in breast cancer tissues. Their co-expression indicates high grade, lymph node metastasis, advanced stage, and poor prognosis. The combined detection of survivin and TK1 is of great significance for evaluating the clinicopathology and prognosis of breast cancer.

    Figures and Tables | References | Related Articles | Metrics
    Clinicopathological analysis of four cases of localized endometrial proliferations of pregnancy and literature review
    HUANG Suming, ZHANG Huijuan, ZHOU Feng
    2025, 24 (05):  529-533.  DOI: 10.16150/j.1671-2870.2025.05.008
    Abstract ( 4 )   HTML ( 0 )   PDF (723KB) ( 2 )  

    Objective To investigate the clinicopathological features of localized endometrial proliferations of pregnancy (LEPP). Methods Clinicopathological data of 4 LEPP patients treated at the International Peace Maternity and Child Health Hospital, Shanghai Jiao Tong University School of Medicine from 2014 to 2024 were collected. Their hematoxylin and eosin (HE)-stained pathological sections were reviewed, immunohistochemical (IHC) testing was performed, and literature was reviewed to summarize clinicopathological characteristics. Results The average age of the 4 patients was 34.5 years (range: 29-40). LEPP was identified in first-trimester abortion specimens in all cases. Microscopically, low-power examination revealed dilated glands arranged in cribriform or papillary patterns, with epithelial hyperplasia and cell stratification. High-power examination showed mild nuclear atypia, with rare mitotic figures (0-1/2 mm²). Calcification was observed in one case. IHC staining demonstrated that all 4 patients were positive for estrogen receptor (ER), progesterone receptor (PR), and paired box gene 2 (PAX2), with stronger expression than in surrounding endometrium. Tumor protein 53 (P53) showed wild-type expression. Mismatch repair proteins were positive. Phosphatase and tensin homolog (PTEN) expression was absent. Literature review indicated that LEPP was characterized by marked glandular epithelial hyperplasia, minimal cytological atypia, and benign biological behavior. Seven cases diagnosed as atypical endometrial hyperplasia or early endometrial carcinoma exhibited morphological features more consistent with LEPP, and no recurrence of endometrial-related diseases was observed during follow-up. Conclusion LEPP is a type of lesion occurring during pregnancy characterized by marked glandular epithelial hyperplasia, minimal cytological atypia, PTEN loss, and PAX2 positivity. It is currently considered biologically benign.

    Figures and Tables | References | Related Articles | Metrics
    Analysis of correlation between thrombelastography and severity of coronary artery lesions in patients with acute coronary syndrome
    XU Shen, SUN Ruizhuang, YU Qin, LIU Qukai, DING Ning
    2025, 24 (05):  534-541.  DOI: 10.16150/j.1671-2870.2025.05.009
    Abstract ( 9 )   HTML ( 1 )   PDF (565KB) ( 6 )  

    Objective To investigate the correlation between thrombelastography (TEG) and the severity of coronary artery lesions in patients with acute coronary syndrome (ACS). Methods A total of 130 patients admitted to the Department of Cardiology of our hospital who underwent coronary angiography and had positive results were consecutively recruited as the ACS group. Meanwhile, 86 patients with ACS excluded by coronary angiography during the same period were selected as the control group. TEG parameters [reaction time (R time), clotting time (K time), blood clot formation rate (Angle α), maximum amplitude (MA)], triglycerides, total cholesterol, high-density lipoprotein, low-density lipoprotein, lactate dehydrogenase, and platelet levels were measured for all subjects. The differences in TEG indicators between the ACS group and control group were compared to identify potential risk factors for ACS. In ACS patients, the correlations of TEG parame-ters with laboratory-related indicators and the severity of coronary artery lesions assessed by the Gensini score were evalua-ted and analyzed. Logistic regression analysis was employed to evaluate the influencing factors of TEG in ACS patients with different numbers of coronary artery lesions. After adjusting for confounding factors, the independent predictive effect of TEG on the risk of ACS was further evaluated. Results The TEG parameters (R time and K time) in the ACS group were lower than those in the control group, and the difference was statistically significant (P<0.01). TEG parameters (R time and K time) were negatively correlated with the Gensini score (rR time=-0.302 3, rK time=-0.257 4, P<0.01). Multivariate logistic regression analysis showed that after adjusting for confounding factors, when TEG (K time) was considered as a categorical variable, Q4 (K time >2.10) was an independent protective factor against ACS (OR=0.34, 95% CI: 0.13-0.87, P<0.05). Receiver operating characteristic (ROC) curve analysis showed that the area under the curve (AUC) of R time and K time for diagnosing ACS was 0.781 0 and 0.605 1, respectively. The TEG parameter (R time) showed a sensitivity of 73.26% and a specificity of 70.00% for diagnosing ACS, while the K time showed a sensitivity of 65.38% and a specificity of 60.47%. Conclusion TEG is associated with ACS and the severity of coronary artery lesions and may serve as an independent predictor of the severity of coronary artery lesions in patients with ACS, which can provide a strong basis for determining whether further invasive diagnosis is needed.

    Figures and Tables | References | Related Articles | Metrics
    Review articles
    Research advances in coagulation factor Ⅷ deficiency
    XIE Liangzhe, DAI Jing, WU Wenman, WANG Xuefeng
    2025, 24 (05):  542-547.  DOI: 10.16150/j.1671-2870.2025.05.010
    Abstract ( 8 )   HTML ( 0 )   PDF (623KB) ( 3 )  

    Coagulation factor Ⅷ (FⅧ) deficiency is a rare bleeding disorder that can manifest as spontaneous or delayed life-threatening hemorrhage. FⅧ is composed of two catalytic subunits (FⅧ-A2) and two carrier (FⅧ-B2) subunits that have several functions in addition to its important role in hemostasis, including angiogenesis, maintenance of pregnancy, wound healing, and bone metabolism. FⅧ deficiencies can be classified as congenital or acquired according to etio-logy. The global incidence of congenital FⅧ deficiency is 0.05 per 100 000. Most patients with congenital FⅧ deficiency typically present with FⅧ-A deficiency. Acquired FⅧ deficiency, which typically arises from factors such as hyperconsumption and decreased synthesis, is more common than the congenital form. In rare instances, patients with acquired FⅧ deficiency may develop inhibitors targeting FⅧ subunits. The occurrence can be idiopathic or associated with comorbidities, such as malignancies or autoimmune disorders. A quantitative functional FⅧ activity assay is the first-line screening test for diagnosing FⅧ deficiency. For congenital FⅧ deficiency, enzyme-linked immunosorbent assays (ELISA) are required to determine the type of deficiency and to detect associated molecular genetic mutations. If acquired FⅧ deficiency is suspected, immunological tests are also required to detect inhibitors. Treatment primarily includes FⅧ replacement therapy and/or immunosuppressive therapy. Therapeutic options for FⅧ replacement have evolved from traditional fresh frozen plasma (FFP), old plasma, whole blood, and cryoprecipitate to plasma-derived and recombinant FⅧ concentrates. Although treatment targets and thresholds for FⅧ deficiency have not been clearly established, timely diagnosis and appropriate management of patients with severe FⅧ deficiency can significantly reduce the morbidity and mortality rates.

    Figures and Tables | References | Related Articles | Metrics
    Advances in research on association between mild behavioral impairment and Alzheimer′s disease
    LI Yuhang, XIAO Shifu, YUE Ling
    2025, 24 (05):  548-554.  DOI: 10.16150/j.1671-2870.2025.05.011
    Abstract ( 5 )   HTML ( 2 )   PDF (683KB) ( 1 )  

    Mild behavioral impairment (MBI) refers to a series of neuropsychiatric symptoms in adults aged ≥50 years, primarily characterized by affective dysregulation and impulse control deficits, including depression, mania, hallucinations, and delusions. As an early harbinger of cognitive decline, MBI is intrinsically linked to the pathological progression of Alzheimer's disease (AD) and may appear several years before the onset of dementia symptoms. Its prevalence is approximately 10% in cognitively normal populations, increasing to 14%-50% among individuals with mild cognitive impairment (MCI). However, in clinical practice, the potential associations between MBI and AD are often underestimated or overlooked due to the complexity and non-specificity of MBI symptoms. In recent years, with in-depth research on AD biomarkers, the intrinsic relationship between MBI and AD has been gradually revealed. Cross-sectional studies have confirmed that MBI is significantly associated with reduced cerebrospinal fluid (CSF) Aβ42 levels and elevated cerebral Aβ deposition burden. Longitudinal evidence further demonstrates positive associations between MBI severity, high Aβ deposition, and accelerated cognitive decline, though its links with tau pathology remain controversial. MBI shows spatial consistency with AD-characteristic brain atrophy, such as in the hippocampus, amygdala, and entorhinal cortex. Collectively, this evidence solidifies the important role of MBI as a neuropsychiatric biomarker in the preclinical stage of AD. To optimize early AD detection, this review aims to highlight the need to establish a multidimensional assessment framework integrating neuropsychiatric symptoms and cognitive decline in clinical practice and remind clinicians to heighten vigilance toward abnormal neuropsychiatric behaviors in the elderly, thereby improving the detection rate of the preclinical stage of AD.

    Figures and Tables | References | Related Articles | Metrics
    Case reports
    Clinicopathological analysis and literature review of SMARCB1-deficient sinonasal carcinoma
    ZHENG Xiangyu, CHEN Jinxiang, LIU Guorong, YANG Yaoxiang, CAI Shaoting, YANG Jing
    2025, 24 (05):  555-561.  DOI: 10.16150/j.1671-2870.2025.05.012
    Abstract ( 9 )   HTML ( 0 )   PDF (8813KB) ( 2 )  

    SMARCB1(SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily B, member 1)-deficient sinonasal carcinoma (SDSC) is a rare and highly aggressive malignant neoplasm of the head and neck region, accounting for 2.7% to 7.0% of primary sinonasal carcinomas. It exhibits a broad age distribution, non-specific clinical manifestations, and histomorphological features that closely mimic various other head and neck malignancies, posing significant diagnostic challenges for pathologists. This report details two SDSC cases treated in the Department of Patho-logy, Guangzhou First People's Hospital. Case 1 was a 75-year-old female who demonstrated combined loss of expression of SMARCB1 (Integrase Interactor 1, INI-1) and SMARCA2(SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily A, member 2) (Brahma Homolog, BRM) proteins. The tumors were mainly located in the right maxillary sinus and nasal cavity. Case 2 was a 60-year-old male who exhibited loss of SMARCB1 (INI-1) expression only. The tumors were located in the left posterior ethmoid sinus. Histologically, both cases were predominantly composed of basaloid cells, interspersed with a minor population of cells exhibiting plasmacytoid/rhabdoid morphology characterized by eccentric nuclei. Case 1 featured extensive geographic tumor necrosis, with only scant residual viable tumor tissue. The clinical stage of both cases was cT4NxM0 at the time of diagnosis. Follow-up: Case 1 received two cycles of induction chemotherapy combined with immunotherapy and died 3 months post-diagnosis. Case 2 underwent extended tumor resection followed by adjuvant therapy and died 12 months post-diagnosis. Comparative analysis revealed that the case with co-loss of SMARCB1 (INI-1) and SMARCA2 (BRM) expression was accompanied by more significant tumor necrosis morphologically and had a shorter survival time. According to literature and database searches worldwide, a total of 236 SDSC cases were reported, with an age range of 25-86 years and a male-to-female ratio of approximately 5:3 to 8:3. Among them, four cases (4/236) showed co-loss of SMARCB1 (INI-1) and SMARCA2 (BRM). However, there are still insufficient data to suggest that such cases have a worse survival prognosis. In conclusion, the overall prognosis of SDSC patients is poor, and there is currently no standard treatment plan. Morphological examination combined with SMARCB1 (INI-1) immunohistochemical testing is the key to definitive diagnosis, and combined detection of SWI/SNF complex member proteins helps identify co-loss cases. Although co-loss cases are rare and the significance of their survival prognosis analysis is unclear, more clinical experience is needed.

    Figures and Tables | References | Related Articles | Metrics
    Medical education
    Preliminary exploration of teaching extramedullary lesions of multiple myeloma via multi-technology and multi-omics
    YU Wenyan, GUO Ying, TANG Yuan, OUYANG Wanyan, HUANG Yan, HU Su, TAO Yi, MI Jianqing
    2025, 24 (05):  562-565.  DOI: 10.16150/j.1671-2870.2025.05.013
    Abstract ( 8 )   HTML ( 1 )   PDF (495KB) ( 2 )  
    Figures and Tables | References | Related Articles | Metrics